Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Prostate cancer in a transgenic mouse.
- N. Greenberg, F. DeMayo, J. Rosen
- Biology, MedicineProceedings of the National Academy of Sciences…
- 11 April 1995
The establishment of breeding lines of transgenic mice that reproducibly develop prostate cancer provides an animal model system to study the molecular basis of transformation of normal prostatic cells and the factors influencing the progression to metastatic prostate cancer.
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.
It is concluded that, by binding to a subset of EREs, the AR can prevent activation of target genes that mediate the stimulatory effects of 17beta-estradiol on breast cancer cells.
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1
Findings show that AR binds and regulates ER cis‐regulatory elements in molecular apocrine tumours, resulting in a transcriptional programme reminiscent of ER‐mediated transcription in luminal breast cancers.
Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease
This study is the first to demonstrate that specific serum miRNAs are common between human prostate cancer and a mouse model of the disease, highlighting the potential of such models for the discovery of novel biomarkers.
Structural and functional consequences of glutamine tract variation in the androgen receptor.
Molecular modeling and the response to cofactors indicate that the increased activity of AR-polyQ2L results from the presentation of a more stable platform for the recruitment of accessory proteins than wild-type AR, and analysis of the relationship between polyQ tract length and AR function revealed a critical size (Q16-Q29) for maintenance of N/C interaction.
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer
- Renee S. Chmelar, G. Buchanan, E. Need, W. Tilley, N. Greenberg
- BiologyInternational journal of cancer
- 15 February 2007
The evidence for deregulated expression and function of the AR and associated coactivators and corepressors and how such events might contribute to the progression of prostate cancer by controlling the selection and expression of AR targets is reviewed.
Regulators of genetic risk of breast cancer identified by integrative network analysis
A breast cancer gene regulatory network was created and asked whether specific regulons are enriched for genes associated with risk loci via expression quantitative trait loci (eQTLs), suggesting shared biology.
Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.
- W. Tilley, G. Buchanan, T. Hickey, J. Bentel
- BiologyClinical cancer research : an official journal of…
- 1 February 1996
The data indicate that AR gene mutations occur commonly in advanced prostate cancers prior to endocrine treatment of disease and may contribute to altered androgen responsiveness of the tumors.
Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
This study demonstrates that AR-Vs broadly restore AR chromatin binding events that are otherwise suppressed during endocrine therapy, and provides pre-clinical rationale for BET inhibition as a strategy for inhibiting expression and Chromatin binding of AR-V in PCa.
Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.
Immunofluorescence, coactivator, and chromatin immunoprecipitation analyses strongly suggest that the effects of alphaSGT on AR function are mediated by interaction in the cytoplasm and are distinct from the receptors response to classic coregulators.